In this study, we used 48 ESCC cell lines and three kinds of anti-EGFR antibodies (Sym004, cetuximab, and panitumumab) to analyze the efficacy of anti EGFR antibodies both in vitro and in vivo. Here, EGFR is linked to esophageal squamous cell carcinoma.